We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Protein Score from Single Plasma Sample Predicts Cardiovascular Disease

By LabMedica International staff writers
Posted on 23 Aug 2023

In a large retrospective analysis, utilizing measurements of plasma proteins from thousands of individuals across primary and secondary event populations, researchers have harnessed artificial intelligence (AI) to create a protein score for predicting major atherosclerotic cardiovascular disease events (ASCVD). More...

The study by scientists from deCODE genetics (Reykjavik, Iceland) was based on an extensive dataset comprising more than 13,500 Icelanders without a history of major ASCVD prior to plasma sampling, as well as over 6,000 participants from the FOURIER trial who had already experienced ASCVD before plasma sampling. In all these cases, plasma protein levels were assessed using the SomaScan platform, measuring approximately 5,000 plasma proteins. Notably, the protein risk score, derived solely from proteomics data of a single plasma sample, effectively predicts ASCVD events even without access to medical history or risk factor information. While much of the risk assessed by the proteins is also reflected in established risk factors, the protein score captures additional risk.

Furthermore, the protein risk score is a dynamic measure. Unlike certain immutable classic risk factors like family history and prior ASCVD events, this score can be modified upon treatment. The dynamic nature of protein risk scores—where protein levels fluctuate in relation to the timing of events—makes them well-suited for predicting event timelines. Consequently, these protein risk scores could prove invaluable in clinical trials for early evaluation of treatment efficacy or risk monitoring.

“We believe that in the proteomic risk score, we may have a biomarker that will allow the world to conduct shorter clinical trials with fewer participants,” said Kari Stefansson, CEO of deCODE genetics and one of the senior investigators of the study. “This is going to make the development of new medicines less expensive and make them available sooner for those who need them. Furthermore, in clinical practice it may allow for more effective prevention of ASCVD.”

Related Links:
deCODE genetics 


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.